Document is current
Any future updates will be listed below
-
Authors
Kan, Xue-Feng
Liang, Bin
Zhang, Xiao-Lin
Yu, Lei
Luo, Yao-Chang
Zhou, Shi
Liu, Rui-Bao
Xu, Guo-Hui
Li, Hai-Liang
Liao, Zheng-Yin
Xiang, Hua
Lu, Wei
Xu, Lin-Feng
Ma, Yi-Long
Xia, Xiang-Wen
Qian, Kun
Dong, Xiang-Jun
Xiong, Fu
Song, Song-Lin
Zhao, Chang
Huang, Ming
Zheng, Chuan-Sheng
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82072041, 81873919)
Outstanding Youth Foundation of Hubei Province (2023AFA107)
Science and Technology Development Foundation Research Fund of Academician Xiaoping Chen for Hepatobiliary and Pancreatic Malignant Tumor (CXPJJH11800001-2018102)
- License Information
-
More Information
Article History
Received: 6 June 2024
Accepted: 21 May 2025
First Online: 28 May 2025
Declarations
:
: This multicenter, randomized, open-label, prospective, phase III trial was carried out in accordance with the principles of the Declaration of Helsinki. The trial protocol was approved by the ethics committee of all participating centers (No. S249-1). All the patients provided a written informed consent before inclusion. This study was registered with the Chinese Clinical Trial Register (Number: ChiCTR1800018621).
: Not applicable.
: The authors declare no competing interests.
